Aerosol deposition in health and disease.

The success of inhalation therapy is not only dependent upon the pharmacology of the drugs being inhaled but also upon the site and extent of deposition in the respiratory tract. This article reviews the main mechanisms affecting the transport and deposition of inhaled aerosol in the human lung. Aerosol deposition in both the healthy and diseased lung is described mainly based on the results of human studies using nonimaging techniques. This is followed by a discussion of the effect of flow regime on aerosol deposition. Finally, the link between therapeutic effects of inhaled drugs and their deposition pattern is briefly addressed. Data show that total lung deposition is a poor predictor of clinical outcome, and that regional deposition needs to be assessed to predict therapeutic effectiveness. Indeed, spatial distribution of deposited particles and, as a consequence, drug efficiency is strongly affected by particle size. Large particles (>6 μm) tend to mainly deposit in the upper airway, limiting the amount of drugs that can be delivered to the lung. Small particles (<2 μm) deposit mainly in the alveolar region and are probably the most apt to act systemically, whereas the particle in the size range 2-6 μm are be best suited to treat the central and small airways.

[1]  S. Sanjar,et al.  Treating systemic diseases via the lung. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[2]  K. Tennal,et al.  Sensitivity of aerosol bolus behavior to methacholine-induced bronchoconstriction. , 1998, Chest.

[3]  J. Heyder,et al.  Total deposition of aerosol particles in the human respiratory tract for nose and mouth breathing , 1975 .

[4]  E. Dekker.  Transition between laminar and turbulent flow in human trachea. , 1961, Journal of applied physiology.

[5]  T. Tuch,et al.  Aerosol bolus dispersion and effective airway diameters in mildly asthmatic children. , 1995, The European respiratory journal.

[6]  J. Heyder,et al.  Effect of cystic fibrosis on inhaled aerosol boluses. , 1989, The American review of respiratory disease.

[7]  C. Kim,et al.  Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. , 1997, American journal of respiratory and critical care medicine.

[8]  T. O'riordan,et al.  Changing patterns of aerosol deposition during methacholine bronchoprovocation. , 1993, Chest.

[9]  G. Rudolf,et al.  Intercomparison of Experimental Regional Aerosol Deposition Data , 1989 .

[10]  G Kim Prisk,et al.  Aerosol deposition in the human lung periphery is increased by reduced-density gas breathing. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[11]  J. Gebhart,et al.  Dose-Dependent Changes of Airway Resistance and Aerosol Pulse Dispersion in Cases of Pharmacologically Induced Airway Obstruction , 1994 .

[12]  P Camner,et al.  Deposition in asthmatics of particles inhaled in air or in helium-oxygen. , 1993, The American review of respiratory disease.

[13]  J. Heyder,et al.  Regional deposition and retention of particles in shallow, inhaled boluses: effect of lung volume. , 1999, Journal of applied physiology.

[14]  G. Smaldone,et al.  Flow limitation, cough, and patterns of aerosol deposition in humans. , 1985, Journal of applied physiology.

[15]  J. Heyder,et al.  Aerosol bolus dispersion in healthy subjects. , 1997, The European respiratory journal.

[16]  F. Lieutier-Colas.  [Deposition of particles in the respiratory tract]. , 2001, Allergie et immunologie.

[17]  J. Marini.  Heliox in chronic obstructive pulmonary disease...time to lighten up? , 2000, Critical care medicine.

[18]  Pieter Zanen,et al.  The optimal particle size for β-adrenergic aerosols in mild asthmatics , 1994 .

[19]  J. Lammers,et al.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.

[20]  Michael Breuer,et al.  Improving prediction of aerosol deposition in an idealized mouth using large-Eddy simulation. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[21]  K. Chung,et al.  Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects. , 1988, The European respiratory journal.

[22]  J. Mitchell,et al.  Do we always need computed tomography to detect and treat parapneumonic pleural effusion? , 2012, European Respiratory Journal.

[23]  G K Prisk,et al.  Convective flow dominates aerosol delivery to the lung segments. , 2011, Journal of applied physiology.

[24]  Gordon Kim Prisk,et al.  Dispersion of 0.5- to 2-μm aerosol in μG and hypergravity as a probe of convective inhomogeneity in the lung , 1999 .

[25]  M. Lippmann,et al.  The regional deposition of inhaled aerosols in man. , 1970, Inhaled particles.

[26]  P. Anderson,et al.  Detection of small airway dysfunction in asymptomatic smokers using aerosol bolus behavior. , 1994, American journal of respiratory and critical care medicine.

[27]  S. Holgate,et al.  Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. , 1988, Thorax.

[28]  Gordon Kim Prisk,et al.  Deposition and dispersion of 1-μm aerosol boluses in the human lung: effect of micro- and hypergravity , 1998 .

[29]  J. Blanchard.  Aerosol bolus dispersion and aerosol-derived airway morphometry: assessment of lung pathology and response to therapy, Part 1. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[30]  J. Heyder,et al.  Aerosol dispersion in human lung: comparison between numerical simulations and experiments for bolus tests. , 1997, Journal of applied physiology.

[31]  H. Wichmann,et al.  Detection of early lung impairment with aerosol bolus dispersion. , 1994, The European respiratory journal.

[32]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[33]  Gerhard Scheuch,et al.  Measurement of lung clearance with pulses of radioactively-labelled aerosols , 1986 .

[34]  M. Svartengren,et al.  Deposition in Man of Particles Inhaled in Air or Helium-Oxygen at Different Flow Rates , 1990 .

[35]  C. Kim,et al.  Assessment of regional deposition of inhaled particles in human lungs by serial bolus delivery method. , 1996, Journal of applied physiology.

[36]  B. Laube,et al.  The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. , 2005, Respiratory care.

[37]  S. Newman.  Deposition and Effects of Inhaled Corticosteroids , 2003, Clinical pharmacokinetics.

[38]  M. Svartengren,et al.  Human lung deposition of particles suspended in air or in helium/oxygen mixture. , 1989, Experimental lung research.

[39]  D. House,et al.  Dispersion of aerosol boluses in the human lung: dependence on lung volume, bolus volume, and gender. , 1995, Journal of applied physiology.

[40]  P. Schaaf,et al.  INFLUENCE OF THE SPATIAL LASER INTENSITY DISTRIBUTION ON LASER NITRIDING OF IRON , 1999 .

[41]  Bernard Altshuler,et al.  Behaviour of Airborne Particles in the Respiratory Tract , 2008 .

[42]  J. Heyder,et al.  Bronchial airway deposition and retention of particles in inhaled boluses: effect of anatomic dead space. , 1998, Journal of applied physiology.

[43]  M. Newhouse,et al.  Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. , 1977, The American review of respiratory disease.

[44]  J. Heyder,et al.  Convective mixing in human respiratory tract: estimates with aerosol boli. , 1988, Journal of applied physiology.

[45]  A. Black,et al.  Regional deposition of 2.5-7.5 μm diameter inhaled particles in healthy male non-smokers , 1978 .

[46]  I. Noth,et al.  The utility of albuterol nebulized with heliox during acute asthma exacerbations. , 2002, American journal of respiratory and critical care medicine.